- News & Events
- Contact Us
Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
Results from the Phase 1 and 2 portions of CHAMPION were presented for 104 patients (Phase 1, n=15; Phase 2, n=89) with relapsed or refractory multiple myeloma who had received one to three prior treatment regimens at the determined maximum tolerated dose (MTD) of 20/70 mg/m2. In the Phase 2 portion of the study, the overall response rate (ORR; defined as the percentage of patients achieving a partial response or better) was 77 percent. The clinical benefit rate (CBR; defined as the percentage of patients with minimal response or better) was 84 percent; the median time to response for patients who achieved a partial response or better was 1.6 months (range, 0.7-7.2); Kaplan-Meier median duration of response (DOR) was 15 months (95 percent CI 9-not estimable); and the Kaplan-Meier median progression-free survival (PFS) was 10.6 months (95 percent CI 9.0-16.1).
"The results from the CHAMPION Phase 1/2 study form the basis of the Phase 3 ARROW study with the goal of potentially providing patients and physicians greater convenience with a once-weekly dosing schedule of Kyprolis," said
The most common hematologic treatment-emergent adverse events (AEs) of any grade were anemia (24 percent), thrombocytopenia (22 percent) and neutropenia (8 percent). The most common non-hematologic treatment-emergent AEs of any grade were fatigue (52 percent), nausea (35 percent), headache and diarrhea (31 percent each). The most commonly occurring grade ≥3 hematologic treatment-emergent AEs were thrombocytopenia (6 percent), anemia (5 percent) and neutropenia (4 percent). The most common non-hematologic grade ≥3 treatment-emergent AEs were fatigue (11 percent), pneumonia (7 percent), acute renal failure and hypertension (6 percent each). Adverse events grade ≥3 included cardiac failure (2 percent) and peripheral neuropathy (1 percent).
A total of 36 patients (35 percent) had at least one serious AE. Sixteen patients (15 percent) treated at the MTD had at least one carfilzomib dose reduction due to AEs, and 10 patients (10 percent) discontinued study treatment due to AEs. Ten patients (10 percent) discontinued treatment due to investigator's discretion, 12 patients (12 percent) discontinued due to patient decision and 34 patients (33 percent) discontinued due to progressive disease. A total of five patients died during the study, all of which were in the Phase 2 portion of the study: one patient each had cause of death reported as cardiopulmonary arrest, pneumonia, disease progression, acute respiratory distress syndrome and acute kidney injury.
The CHAMPION (Community Harmonized Assessment of Myeloma Patients via an Integrated Oncology Network) trial is a Phase 1/2, multicenter, single-arm, non-randomized, open-label and dose-escalation study of weekly Kyprolis with dexamethasone for patients with relapsed or refractory multiple myeloma. The primary objective of the Phase 1 portion of the study was to determine the MTD of once-weekly Kyprolis with dexamethasone. The primary objective of the Phase 2 portion of the study was to determine the ORR. Secondary endpoints were to evaluate the CBR, PFS, time to progression and DOR. Patients who received one to three prior treatment regimens were eligible to enroll. The last patient was enrolled in
For more information about CHAMPION, please visit www.clinicaltrials.gov under trial identification number NCT01677858.
The ARROW (RAndomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-Weekly versus Twice-weekly Carfilzomib Dosing) trial is evaluating approximately 460 patients with relapsed and refractory multiple myeloma who have received at least two but no more than three prior therapies, including bortezomib and an IMiD. Those included in the study will be randomized to receive once-weekly Kyprolis (20 mg/m2 on day 1 of cycle 1, 70 mg/m2 on days 8 and 15 of cycle 1 and 70 mg/m2 on days 1, 8 and 15 of subsequent cycles) with dexamethasone (40 mg) versus twice-weekly Kyprolis (20 mg/m2 on days 1 and 2 of cycle 1, 27 mg/m2 on days 8, 9, 15 and 16 of cycle 1 and 27 mg/m2 on days 1, 2, 8, 9, 15 and 16 of subsequent cycles) with dexamethasone (40 mg). The primary endpoint of the trial is ORR, defined as the proportion of subjects achieving a best overall response of partial response, very good partial response, complete response or stringent complete response based on the International Myeloma Working Group Uniform Response Criteria. Secondary endpoints include PFS, overall survival and safety and tolerability. The trial is being conducted in approximately 100 sites worldwide. For more information about this trial, please visit www.clinicaltrials.gov under trial identification number NCT02412878.
About Multiple Myeloma
Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow.1,2 Worldwide, nearly 230,000 people are living with multiple myeloma and approximately 114,000 new cases are diagnosed annually.3 In the U.S., there are nearly 96,000 people living with, or in remission from, multiple myeloma. The estimated number of new cases of multiple myeloma in 2014 was more than 24,000 and the estimated number of deaths was 11,090.4 In
Amgen Post-ASCO Summary Webcast
Live audio of the event will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in
About Kyprolis® (carfilzomib) for Injection
Kyprolis is a product of
Important Safety Information Regarding Kyprolis® (carfilzomib) for Injection
This safety information is specific to the current U.S. approved indication, which is based on Phase 2 studies.
Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. There were 37 deaths in the Phase 2 studies, or 7 percent of patients. The most common causes of death, other than disease progression, were cardiac (5 patients), end-organ failure (4 patients) and infection (4 patients). Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia, pulmonary hypertension, pulmonary complications, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.
Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications.
Pulmonary arterial hypertension (PAH) was reported in 2 percent of patients treated with Kyprolis and was Grade 3 or greater in less than 1 percent of patients. Dyspnea was reported in 35 percent of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5 percent; no Grade 4 events and 1 death (Grade 5) was reported.
Infusion reactions, characterized by a spectrum of systemic symptoms including fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina can occur immediately following or up to 24 hours after administration of Kyprolis. Administration of dexamethasone prior to Kyprolis reduces the incidence and severity of reactions. Tumor lysis syndrome (TLS) occurred following Kyprolis administration in <1 percent of patients. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS.
Thrombocytopenia following Kyprolis administration resulted in a dose reduction in 1 percent of patients and discontinuation of treatment with Kyprolis in <1 percent of patients.
Cases of hepatic failure, including fatal cases, have been reported (<1 percent). Kyprolis can cause elevations of serum transaminases and bilirubin.
Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fata outcome have been reported. Treatment with Kyprolis should be discontinued if signs and symptoms of TTP/HUS occur.
Cases of posterior reversible encephlophay syndrome (PRES) have been reported. Treatment with Kyprolis should be discontinued if PRES is suspected.
There are no adequate and well-controlled studies in pregnant women using Kyprolis. Females of reproductive potential should be advised to avoid becoming pregnant while being treated with Kyprolis.
The most common serious adverse reactions were pneumonia, acute renal failure, pyrexia and congestive heart failure. The most common adverse reactions (incidence of 30 percent or greater) observed in clinical trials of patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea and pyrexia. Serious adverse reactions were reported in 45 percent of patients.
Full prescribing information is available at www.kyprolis.com.
This news release contains forward-looking statements that are based on the current expectations and beliefs of
No forward-looking statement can be guaranteed and actual results may differ materially from those
In addition, sales of
The scientific information discussed in this news release relating to new indications for
Dimopoulos, M.A. Multiple Myeloma. Annals of Oncology 21 (Supplement 7): vii143–vii150, 2010.
National Cancer Institute. SEER Stat Fact Sheets: Myeloma. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed May 2015.
International Agency for Research on Cancer, GLOBOCAN 2012 database. Available at http://globocan.iarc.fr/. Accessed May 2015.
Leukemia & Lymphoma Society. Facts 2014-2015. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf. Accessed May 2015.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amgen-initiates-phase-3-study-evaluating-once-weekly-kyprolis-carfilzomib-in-patients-with-relapsed-and-refractory-multiple-myeloma-300091295.html